Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Novo Nordisk signs deal for monthly GLP-1 agonist Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases
Beginning in 2027, popular GLP-1 medications, Ozempic, Rybelsus, and Wegovy, will become MFP drugs
Shield it from direct light and moisture
Changes in body weight, body composition, and food intake were the primary endpoints
We observed lower expression of CCR2 on HUVEC treated with PCa supernatant (PC-3, LNCaP) exposed 24 h to ALCAR
US$ 29.95
US$ 22.64
US$ 20.81
